Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company’s prior ...
Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success BiomX expects FDA feedback on BX004 clinica ...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2025. "Our recent ...
Pharma R&D tends to be a step-by-step process, whereas biotech research is more experimental and involves many different ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback